Meningitis vaccine drug interactions

Meningitis vaccine

MENVEO® FDA Package Insert
Description
Clinical Pharmacology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  Chetan Lokhande, M.B.B.S [2]

## DRUG INTERACTIONS

[edit | edit source]

### Concomitant Administration with Other Vaccines

[edit | edit source]

Do not mix MENVEO or any of its components with any other vaccine or diluent in the same syringe or vial.

In two clinical trials of infants initiating vaccination at 2 months of age 1, 3, MENVEO was given concomitantly at 2, 4 and 6 months with routine infant vaccines: diphtheria toxoid, acellular pertussis, tetanus toxoid, inactivated polio types 1, 2 and 3, hepatitis B, Haemophilus influenzae type b (Hib) antigens; pentavalent rotavirus, and 7-valent pneumococcal conjugate vaccine. For dose 4 given at 12 months of age, MENVEO was given concomitantly with the following vaccines: 7-valent pneumococcal conjugate, MMRV or MMR+V, and inactivated hepatitis A. In a clinical trial of older infants (≥ 7 months of age) and toddlers 5, MENVEO was administered concomitantly with MMRV or MMR+V vaccine(s) at 12 months of age. No immune interference was observed for the concomitantly administered vaccines, including most pneumococcal vaccine serotypes (post-dose 3); no immune interference was observed post-dose 4 for any pneumococcal vaccine serotypes1.[See Immunogenicity of Concomitantly Administered Vaccines ]

For children 2 years through 10 years of age, no data are available to evaluate safety and immunogenicity of other childhood vaccines when administered concomitantly with MENVEO.

In a clinical trial in adolescents 14, MENVEO was given concomitantly with the following: Tdap and HPV, no interference was observed in meningococcal immune responses when compared to MENVEO given alone. Lower geometric mean antibody concentrations (GMCs) for antibodies to the pertussis antigens filamentous hemagglutinin (FHA) and pertactin were observed when MENVEO was administered concomitantly with Tdap and HPV as compared with Tdap alone. [See Immunogenicity of Concomitantly Administered Vaccines]

### Immunosuppressive Treatments

[edit | edit source]

Immunosuppressive therapies, such as irradiation, antimetabolite medications, alkylating agents, cytotoxic drugs, and corticosteroids (when used in greater than physiologic doses) may reduce the immune response to MENVEO [See Altered Immunocompetence ]. The immunogenicity of MENVEO has not been evaluated in persons receiving such therapies.[1]

## References

[edit | edit source]

1. ↑ "http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=89dde472-1efb-4630-88bc-41cde216fb3a". External link in `|title=` (help)

Adapted from the FDA Package Insert.